A Role for Germline Variants in Multiple Myeloma?
| dc.contributor.author | Walker, Brian A. | |
| dc.contributor.department | Medicine, School of Medicine | |
| dc.date.accessioned | 2025-06-13T07:22:02Z | |
| dc.date.available | 2025-06-13T07:22:02Z | |
| dc.date.issued | 2024 | |
| dc.description.abstract | In Blood Cancer Discovery, Thibaud and colleagues report the incidence of pathogenic germline variants (PGV) in patients with multiple myeloma and that these PGVs are associated with DNA repair pathway genes, including BRCA1 and BRCA2. They find an association of patients with PGVs and previous family or personal history of cancer, and that these patients are diagnosed slightly earlier than those without PGVs. Patients with PGVs had a longer progression-free survival than those without PGVs when they received high-dose melphalan and autologous stem cell transplant, providing a therapeutic rationale for diagnostic germline testing in myeloma. See related article by Thibaud et al., p. 428. | |
| dc.eprint.version | Final published version | |
| dc.identifier.citation | Walker BA. A Role for Germline Variants in Multiple Myeloma?. Blood Cancer Discov. 2024;5(6):375-376. doi:10.1158/2643-3230.BCD-24-0226 | |
| dc.identifier.uri | https://hdl.handle.net/1805/48670 | |
| dc.language.iso | en_US | |
| dc.publisher | American Association for Cancer Research | |
| dc.relation.isversionof | 10.1158/2643-3230.BCD-24-0226 | |
| dc.relation.journal | Blood Cancer Discovery | |
| dc.rights | Publisher Policy | |
| dc.source | PMC | |
| dc.subject | Genetic predisposition to disease | |
| dc.subject | Multiple myeloma | |
| dc.subject | Germ-line mutation | |
| dc.title | A Role for Germline Variants in Multiple Myeloma? | |
| dc.type | Article | |
| ul.alternative.fulltext | https://pmc.ncbi.nlm.nih.gov/articles/PMC11528183/ |